Bicycle Therapeutics PLC (BCYC) stock
BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 11/3079% below fair value
$3.37−0.08 (-2.32%)
Close on Nov 13, 2026Market cap $236.22MP/E –Yield 0.00%
Bicycle Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Bicycle Therapeutics's enterprise value was -$252.44M on Nov 11, 2026, against -$129.91M a year earlier. Over the last 5 years it ranged from -$312.02M to $1.33B, with a median of $281.47M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$252.44M | – |
| 2025 | Dec 31, 2025 | -$157.63M | -309.2% |
| 2024 | Dec 31, 2024 | $75.36M | -66.5% |
| 2023 | Dec 29, 2023 | $224.84M | -58.9% |
| 2022 | Dec 30, 2022 | $547.24M | -58.8% |
| 2021 | Dec 31, 2021 | $1.33B | +452.5% |
| 2020 | Dec 31, 2020 | $240.38M | +229.9% |
| 2019 | Dec 31, 2019 | $72.87M | – |
See a number that looks wrong?